سعر مابثيرا 1400مجم/11.7 مل فيال تحت الجلد 2026

MabThera 1400 mg/11.7 mL (Egypt; Roche): rituximab 120 mg/mL solution for subcutaneous injection in one vial, for non-Hodgkin's lymphoma after a first full intravenous dose.

• Adults with non-Hodgkin's lymphoma: previously untreated stage III-IV follicular lymphoma with chemotherapy; maintenance in follicular lymphoma responding to induction; CD20-positive diffuse large B-cell NHL with CHOP.Population: AdultsEuropean Medicines Agency (EMA)

• NHL/CLL: infusion-related reactions are the most frequent (majority of patients at the first infusion, <1% after eight doses); infections in about 30-55% (NHL) and 30-50% (CLL) of trial patients; serious reactions include infusion reactions, infections, cardiovascular events, hepatitis B reactivation and PML.International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to rituximab, murine proteins, hyaluronidase or excipients; active severe infections; severely immunocompromised state.International label, same product · European Medicines Agency (EMA)

• Infusion/administration-related reactions (including cytokine-release and tumour-lysis syndrome), serious infections, hepatitis B reactivation (screen all patients for HBV before treatment), progressive multifocal leukoencephalopathy, cardiovascular events and severe skin reactions (TEN, Stevens-Johnson syndrome) are described; record trade name and batch number.International label, same product · European Medicines Agency (EMA)
• The safety of immunisation with live viral vaccines after MabThera has not been studied.International label, same product · European Medicines Agency (EMA)

• IgG crosses the placenta; transient B-cell depletion and lymphocytopenia have been reported in infants exposed in utero; do not give in pregnancy unless the possible benefit outweighs the risk; women of childbearing potential should use effective contraception during and for 12 months after treatment.International label, same product · European Medicines Agency (EMA)
• Very low concentrations in milk (relative infant dose <0.4%); because data are limited, breast-feeding is not recommended during treatment and optimally for 6 months after.International label, same product · European Medicines Agency (EMA)

• Rituximab: Binds the CD20 antigen on B lymphocytes and mediates B-cell lysis (genetically engineered chimeric antibody produced in CHO cells).